07:00 , May 25, 2015 |  BioCentury  |  Finance

Innovation underfed

Stephen Hansen, Associate Editor   Europe's Iceberg 2015 Despite world-class research institutions and a crop of novel drugs making their way through the clinic, European biotech is finding it hard to reach the end zone with its...
07:00 , Mar 31, 2014 |  BioCentury  |  Finance

LSP's steady hand

When LSP-Life Sciences Partners launches a new healthcare venture fund next year it will stick to a strategy that has yielded 12 exits in the past 18 months - early stage, European drug development companies....
07:00 , Jun 18, 2012 |  BC Week In Review  |  Company News

4SC board of directors update

4SC AG (Xetra:VSC), Planegg-Martinsried, Germany   Business: Autoimmune, Cancer   Appointed: Manfred Ruediger, CEO of Affectis Pharmaceuticals AG and Kiadis Pharma B.V., as deputy chairman; and Thomas Werner, formerly deputy chairman, as chairman   ...
07:00 , May 17, 2012 |  BC Innovations  |  Targets & Mechanisms

Paradoxical P2X7

Italian researchers have shown in vivo that inhibiting the P2X7 receptor, rather than agonizing it as previously thought, can treat cancer.1 The findings could open up a new disease area for companies developing P2X7 antagonists...
07:00 , May 3, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Purinergic receptor P2X ligand-gated ion channel 7 (P2RX7; P2X7) Mouse studies suggest inhibiting P2X7 could help...
07:00 , Apr 5, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Purinergic receptor P2X ligand-gated ion channel 7 (P2RX7; P2X7) Mouse and human studies suggest inhibiting P2X7...
07:00 , Mar 19, 2012 |  BioCentury  |  Strategy

Remaking Merck Serono

Five years after spending $13.2 billion to acquire Serono S.A. as a growth platform, Merck KGaA finds itself with much higher pharmaceutical sales than it could have achieved on its own, but no obvious way...
08:00 , Jan 5, 2012 |  BC Innovations  |  Cover Story

No place like inflammasome

Researchers at Virginia Commonwealth University have found that inhibiting inflammasome formation with antagonists of the membrane receptor P2X7 could help prevent heart failure following acute myocardial infarction.1 The findings point to a repurposing opportunity for...
08:00 , Dec 12, 2011 |  BioCentury  |  Finance

Venture, de-instituted

Venture, de-instituted Early stage life sciences investor EMBL Ventures had a first close of €40 million ($53.7 million) on its second fund without the participation of institutional investors who are focused on liquidity, the firm's Jan...
07:00 , Jun 23, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Arterial thrombosis Purinergic receptor P2X ligand-gated ion channel 7 (P2RX7; P2X7) Mouse studies suggest inhibiting P2RX7...